- In April 2023, the Cyclic Vomiting Syndrome Association (CVSA) partnered with major pediatric research hospitals in North America to launch a multicenter clinical registry, aimed at improving diagnosis, treatment protocols, and long-term monitoring of CVS. This initiative is a significant step toward evidence-based care, helping clinicians identify patterns, triggers, and effective therapies, while reinforcing the importance of cross-institutional collaboration in managing rare gastrointestinal disorders
- In March 2023, Ironwood Pharmaceuticals, Inc., known for its work in gastrointestinal therapies, initiated a Phase II trial exploring the off-label use of a neuromodulator in adult CVS patients. The trial seeks to evaluate the drug's efficacy in reducing the frequency and severity of vomiting episodes by targeting the gut-brain axis. This development reflects growing interest from pharmaceutical companies in repurposing treatments for functional GI disorders such as CVS
- In March 2023, researchers from Tokyo University Hospital published findings on genetic predispositions and mitochondrial dysfunction in CVS, offering new insight into the condition's pathophysiology. The study emphasizes personalized medicine and has opened avenues for developing targeted therapies in both pediatric and adult patients. This advancement highlights the region’s role in foundational research into the biological basis of CVS
- In February 2023, Children’s Hospital Colorado launched a specialized telehealth program for managing CVS in rural and underserved areas. By combining behavioral therapy, dietary counseling, and pharmacologic care, this program improves access to consistent, multidisciplinary treatment. The initiative demonstrates how technology is being leveraged to close gaps in care for rare and chronic gastrointestinal conditions
- In January 2023, Mayo Clinic announced enhancements to its integrated care model for functional GI disorders, including CVS, with a focus on biofeedback and cognitive behavioral therapy (CBT). This update integrates psychological and physiological treatment methods, underlining the importance of a holistic approach. It represents a growing recognition within the medical community of the biopsychosocial nature of cyclic vomiting syndrome
